New combo therapy shows promise for kids with tough cancers

NCT ID NCT03585465

Terminated Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of an immunotherapy drug (nivolumab) and low-dose chemotherapy in children and teenagers whose solid tumors had not responded to standard treatments. The goal was to see if the combination was safe and could help control the cancer. The trial was stopped early, but it aimed to find better ways to manage these difficult-to-treat cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHILDHOOD SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

childhood neoplasm embryonal neoplasm ependymoma Ewing sarcoma low grade glioma malignant glioma neoplasm neuroblastoma rhabdomyosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHILDHOOD SOLID TUMOR

Contacts and locations

Locations

Centre Léon Bérard (IHOPe)

Lyon, France
Centre Oscar Lambret

Lille, France
Cliniques Universitaires Saint-Luc (CUSL)

Brussels, Belgium
Hôpital La Timone, AP-HM

Marseille, France
Hôpital Mère-Enfant, CHU Nantes

Nantes, France
Hôpital d'Enfants - CHRU Nancy

Nancy, France
Hôpital de Hautepierre, CHRU Strasbourg

Strasbourg, France
Hôpital des Enfants - CHU Toulouse

Toulouse, France
Institut Curie

Paris, France
University Hospital Ghent

Ghent, Belgium
University Hospital Leuven

Leuven, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.